Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BiomX ( (PHGE) ) has issued an update.
On March 11, 2026, BiomX Inc. held a special meeting of stockholders, reconvened after adjournment from February 25, 2026, at which all 1,593,516 outstanding common shares were represented and voted with no broker non-votes recorded. Shareholders approved all proposals, including authorization under NYSE American rules for the issuance of more than 19.99% of the company’s outstanding common stock in connection with Series Y convertible preferred stock and warrants from prior financing agreements.
The approved authorization enables BiomX to issue common shares underlying its Series Y preferred stock and related warrants tied to a December 26, 2025 securities purchase agreement and a November 26, 2025 placement engagement, including shares issuable as dividends or via price adjustments, thereby facilitating the completion and flexibility of its financing structure. Stockholders also approved a potential adjournment mechanism for the meeting, though no adjournment was ultimately required, confirming strong support for the capital issuance plan and reducing procedural risk around the financing.
The most recent analyst rating on (PHGE) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity) and a short cash runway highlighted in the latest earnings call. Technical indicators are moderately supportive with neutral momentum and price above key short/intermediate moving averages, but valuation remains challenged due to a negative P/E and no dividend support.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. is a publicly traded biotechnology company focused on developing therapeutic products, with its capital structure centered on common stock and preferred stock instruments listed on the NYSE American market. The company engages in securities offerings and related financing arrangements to support its operations and strategic initiatives within the life sciences sector.
Average Trading Volume: 1,050,170
Technical Sentiment Signal: Sell
Current Market Cap: $11.95M
See more data about PHGE stock on TipRanks’ Stock Analysis page.